B7-H6 Protein (AA 25-262) (Fc Tag,AVI tag,Biotin)

N° du produit ABIN6972948

Détail du produit

Antigène: B7-H6 (NCR3LG1) (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 (NCR3LG1))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 25-262

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette B7-H6 protéine est marqué à la Fc Tag,AVI tag,Biotin.

Specificité: Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Attributs du produit: Biotinylated Human B7-H6 / NCR3LG1 Protein, Fc,Avitag™

Pureté: >95 % as determined by SDS-PAGE.

niveau d'endotoxine: Less than 1.0 EU per μg by the LAL method.

Information d'application

Commentaires:

Ready-to-use Avitag™ biotinylated protein:
The product is exclusively produced using the Avitag™ technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.

This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: PBS, pH 7.4

Stock: -20 °C

Détail du antigène

Antigène: B7-H6 (NCR3LG1) (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1 (NCR3LG1))

Autre désignation: B7-H6 (NCR3LG1 Produits)

Synonymes: B7-H6 Protein, B7H6 Protein, DKFZp686O24166 Protein, natural killer cell cytotoxicity receptor 3 ligand 1 Protein, NCR3LG1 Protein

Sujet: The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene, however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.

Poids moléculaire: 54.8 kDa